Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Male Reproductive SystemDRG 712-testes-procedures-without-cc-mcc
    Ask Trek AI about this page

    Testes Procedures without CC/MCC: Inpatient Reimbursement Overview

    DRG 712 encompasses inpatient admissions for testes procedures without a Complication or Comorbidity or a Major Complication or Comorbidity, covering procedures such as orchiectomy and testicular exploration. This classification is important for inpatient reimbursement because Diagnosis-Related Group assignment determines Centers for Medicare & Medicaid Services prospective payment amounts and reflects the expected resource use for these straightforward urologic surgical cases.

    Customize your policy alerts

    Sign up for drg 712 policy alerts

    Get alerted when payer policies referencing 712 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 712 Overview

    DRG 712 covers inpatient hospital admissions for testes procedures without a Complication or Comorbidity or a Major Complication or Comorbidity, generally including straightforward orchiectomy, testicular exploration, and related operative interventions when no significant comorbid conditions are coded. This Diagnosis-Related Group groups cases with expected lower resource use and shorter lengths of stay compared with more complex urologic surgical admissions. It matters for Centers for Medicare & Medicaid Services payment because hospitals are reimbursed based on the assigned Diagnosis-Related Group, which affects prospective payment amounts for these procedures. Accurate coding of procedures and comorbidities determines whether an admission qualifies for this classification and the associated inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative analgesia and anesthesia optimization studies: randomized or pragmatic trials comparing different intraoperative and immediate postoperative anesthesia techniques, local/regional blocks, and multimodal analgesic protocols for patients undergoing inpatient testes surgical procedures (e.g., orchiectomy, orchidopexy, hydrocelectomy). These studies enroll adult and adolescent surgical patients in the acute perioperative period to assess pain control, opioid-sparing effects, length of stay, and short-term complication rates. Results are directly relevant to surgeons, anesthesiologists, and payers because improved perioperative protocols can reduce opioid use, decrease inpatient days and readmissions, and lower overall episode cost.
    • Comparative effectiveness research on procedural approaches and surgical techniques: prospective cohort studies or randomized trials comparing open, minimally invasive, or tissue-sparing techniques and variations in hemostatic or reconstructive methods for common inpatient testes procedures. These studies focus on operative time, intraoperative blood loss, wound complications, functional outcomes (e.g., testicular viability, fertility-related metrics when applicable), and need for reoperation among heterogeneous patients including those with traumatic, infectious, or neoplastic indications. Findings inform clinicians and hospital administrators about which approaches yield lower complication rates and resource utilization, guiding clinical pathways and reimbursement policy decisions.
    • Post-discharge outcomes and utilization studies: longitudinal observational research examining 30- to 90-day readmissions, emergency visits, patient-reported outcomes (pain, physical function, sexual/reproductive concerns), and downstream costs for patients discharged after inpatient testes procedures. These studies include varied populations—older adults, patients with comorbidities, and those with social determinants affecting recovery—to identify predictors of adverse events and unmet post-acute needs. Insights support care coordination interventions, targeted discharge planning, and payer strategies to reduce preventable readmissions and optimize value across the surgical episode.

    Related Codes

    707-MAJOR-MALE-PELVIC-PROCEDURES-WITH-CC-MCC

    Major Male Pelvic Procedures with CC/MCC: Inpatient Reimbursement Overview

    708-MAJOR-MALE-PELVIC-PROCEDURES-WITHOUT-CC-MCC

    Major Male Pelvic Procedures without CC/MCC: Inpatient Reimbursement Overview

    709-PENIS-PROCEDURES-WITH-CC-MCC

    Penis Procedures with CC/MCC: Inpatient Reimbursement Overview

    710-PENIS-PROCEDURES-WITHOUT-CC-MCC

    Penis Procedures without CC/MCC: Inpatient Reimbursement Overview

    711-TESTES-PROCEDURES-WITH-CC-MCC

    Testes Procedures with CC/MCC: Inpatient Reimbursement Overview

    713-TRANSURETHRAL-PROSTATECTOMY-WITH-CC-MCC

    Transurethral Prostatectomy with CC/MCC: Inpatient Reimbursement Overview

    714-TRANSURETHRAL-PROSTATECTOMY-WITHOUT-CC-MCC

    Transurethral Prostatectomy without CC/MCC: Inpatient Reimbursement Overview

    715-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-FOR-MALIGNANCY-WITH-CC-MCC

    Other Male Reproductive System O.R. Procedures for Malignancy with CC/MCC: Inpatient Reimbursement Overview

    716-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-FOR-MALIGNANCY-WITHOUT-CC-MCC

    Other Male Reproductive System O.R. Procedures for Malignancy without CC/MCC: Inpatient Reimbursement Overview

    717-OTHER-MALE-REPRODUCTIVE-SYSTEM-O-R-PROCEDURES-EXCEPT-MALIGNANCY-WITH-CC-MCC

    Other Male Reproductive System O.R. Procedures Except Malignancy with CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 20

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.